Personalized Diagnostics for Neurological Disorders

An industry first, Circular Genomics is developing a platform leveraging a novel and stable form of RNA, known as circular RNAs, as biomarkers to help patients suffering from psychiatric and neurological disorders find the most effective personalized treatment. The company’s first product aims to predict a patient’s sensitivity to anti-depressants before treatment, allowing clinicians to make better choices and provide faster, more effective relief for patients.